Modelos de dados selecionados

Deve ter sessão iniciada para selecionar vários modelos de dados e para os transferir ou analisar.

19 Resultados da pesquisa.
Relevância Avaliação Novos primeiro Antigos primeiro

CDASH Concomitant Medication - Concomitant medication

- 20.06.18 - 1 Formulário, 2 Grupos de itens, 9 Elementos de dados, 2 Idiomas
Grupos de itens: General information, Details
translated and modified from CDASH 2011-10-24 http://www.cdisc.org

Visit 9 Diabetes Mellitus-ASP1941-1941-CL-0004 NCT01071850

- 19.02.22 - 1 Formulário, 10 Grupos de itens, 45 Elementos de dados, 1 Idioma
Grupos de itens: Date of Visit, Physical Examination, Orthostatic vital signs, 12 Lead ECG, Weight, Waist and Hip Circumference, Pregnancy Test, EQ-5D, ADDQol, Diab-MedSat
A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Subjects with Type 2 Diabetes MellitusTEST Study Visit 9

Early Discontinuation Diabetes Mellitus-ASP1941-1941-CL-0004 NCT01071850

- 18.02.22 - 1 Formulário, 10 Grupos de itens, 45 Elementos de dados, 1 Idioma
Grupos de itens: Date of Visit, Physical Examination, Orthostatic vital signs, 12 Lead ECG 1, Weight, Waist and Hip Circumference, Pregnancy Test, EQ-5D, ADDQol, Diab-MedSat
A Phase 2, Double-Blind, Randomized, Placebo and Active-Controlled Dose-Finding Study to Assess the Efficacy, Safety and Tolerability of Multiple Oral Doses of ASP1941 in Subjects with Type 2 Diabetes MellitusTEST Study Early Discontinuation

Comparison of pharmacokinetic and tolerability of ropinirole in healthy adults, 101468/198 - Prior Medication

- 20.09.21 - 1 Formulário, 2 Grupos de itens, 12 Elementos de dados, 1 Idioma
Grupos de itens: Administrative data, Prior Medication
Study ID: 101468/198 Clinical Study ID: 101468/198 Study Title:An open, randomised, crossover, healthy volunteer study to compare the PK and tolerability of ropinirole as 3 different new formulations with the standard marketed formulation and to study the effects of a high fat meal on a new formulation Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 1 Study Recruitment Status: Completed Generic Name: ropinirole Trade Name: Modutab,ZIPEREVE,ZEPREVE,REPREVE,ADARTREL,REQUIP,Zygara; Zygara,ZIPEREVE,ZEPREVE,Requip Depot,REQUIP,REPREVE,Modutab,ADARTREL Study Indication : Restless Legs Syndrome The Study consists of a Screening, 5 Sessions each with 2 days and a Follow-up. This document contains the prior medication form. It has to be filled in for screening.

Treatment - Study Medication Administration - 3280117v1.0 - Study Medication Administration

- 20.09.21 - 1 Formulário, 1 Grupo de itens, 16 Elementos de dados, 1 Idioma
Grupo de itens: Study Medication Administration
Record study medication administration. Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=AD24494B-49FC-235C-E040-BB89AD4305F5

EUROASPIRE III- Coronary heart disease Medication Patient Interview - Medication Patient Interview

- 17.09.21 - 1 Formulário, 2 Grupos de itens, 96 Elementos de dados, 1 Idioma
Grupos de itens: Demographic Information, Medication
Provided by Prof. Keil Source: Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009 Mar 14;373(9667):929-40. doi: 10.1016/S0140-6736(09)60330-5. PubMed PMID: 19286092

EUROASPIRE III- Coronary heart disease Medication at discharge - Medication at discharge

- 17.09.21 - 1 Formulário, 2 Grupos de itens, 97 Elementos de dados, 1 Idioma
Grupos de itens: Demographic Information, Medication
Provided by Prof. Keil Source: Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009 Mar 14;373(9667):929-40. doi: 10.1016/S0140-6736(09)60330-5. PubMed PMID: 19286092

Ropinirole Case Report Form GSK RRL100013 - NON-SERIOUS ADVERSE EVENT

- 17.09.21 - 9 Formulários, 2 Grupos de itens, 13 Elementos de dados, 1 Idioma
Grupos de itens: NON-SERIOUS ADVERSE EVENT, NON-SERIOUS ADVERSE EVENTS
Ropinirole Case Report Form GSK RRL100013 GSK Study ID: 100013 Clinical Study ID: RRL100013 A 12-Week, Double-Blind, Placebo-Controlled, Twice-Daily Dosing Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering from Restless Legs Syndrome (RLS) Requiring Extended Treatment Coverage

Ropinirole Case Report Form GSK RRL100013

3 Grupos de itens 14 Elementos de dados

STATUS OF TREATMENT BLIND

3 Grupos de itens 14 Elementos de dados

Investigator INSTRUCTIONS

1 Grupo de itens 1 Elemento de dados

INVESTIGATIONAL PRODUCT

1 Grupo de itens 8 Elementos de dados

CONCOMITANT MEDICATIONS

1 Grupo de itens 10 Elementos de dados

Vital signs descirptions

1 Grupo de itens 11 Elementos de dados

Persönliches Interview SHIP-Trend-1 Medikamentenanamnese

- 19.02.21 - 1 Formulário, 1 Grupo de itens, 60 Elementos de dados, 1 Idioma
Grupo de itens: Medikamentenanamnese
Medikamentenanamnese form of SHIP Study (Study of Health in Pomerania), conducted by the University Medicine of Greifswald. SHIP unique domain name TREND.TREND1.INT.MEDIK.MEDIK. ODM derived from https://www.fvcm.med.uni-greifswald.de/dd_service/data_use_explore.php. Further information: http://www2.medizin.uni-greifswald.de/cm/fv/ship.html. Publication granted by Prof. Völzke. Reference: Völzke H, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294-307. PMID: 20167617

Effects of Low-fat and high-fat meals on the Pharmacokinetics of Lapatinib in ErB2+ Breast Cancer patients, NCT00821054 - Lapatinib

- 20.07.20 - 1 Formulário, 3 Grupos de itens, 9 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Lapatinib Dosing, Treatment confirmation
Study ID: 111582 Clinical Study ID: 111582 Study Title: An Open Label Study to Examine the Effects of Low-fat and High-fat Meals on the Pharmacokinetics of Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00821054 https://clinicaltrials.gov/ct2/show/NCT00821054 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Lapatinib Trade Name: N/A Study Indication: Neoplasms, Breast The study consists of a screening, four study visits at day-1, week 1, 2 and 3 and a follow-up visit. This document contains the Lapatinib Dosing information. It has to be filled in once for each week 1, week 2 and week 3.

Effects of Low-fat and high-fat meals on the Pharmacokinetics of Lapatinib in ErB2+ Breast Cancer patients, NCT00821054 - Lapatinib diary

- 04.07.20 - 1 Formulário, 7 Grupos de itens, 10 Elementos de dados, 1 Idioma
Grupos de itens: Administrative Data, Week number and study day, Predose Overnight Fast, Lapatinib Dosage, Count of entities, Postdose Fasting, Post-dose Vomiting, Therapeutic procedure, Confirmation
Study ID: 111582 Clinical Study ID: 111582 Study Title: An Open Label Study to Examine the Effects of Low-fat and High-fat Meals on the Pharmacokinetics of Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00821054 https://clinicaltrials.gov/ct2/show/NCT00821054 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: Lapatinib Trade Name: N/A Study Indication: Neoplasms, Breast The study consists of a screening, four study visits at day-1, week 1, 2 and 3 and a follow-up visit. This document contains the Lapatinib diary. This form is for dosing and meal data from the diary only. Go to visits Week 1 to Week 3 for Lapatinib and Meal data from clinic visits. This form has to be filled in for each week and each study day of the trial.

FHIR v4.0.1 - Resource Medication (3)

- 09.03.20 - 1 Formulário, 1 Grupo de itens, 5 Elementos de dados, 1 Idioma
Grupo de itens: Medication
This form contains an incomplete implementation of the FHIR Resource Medication, v4.0.1 . After preliminary review, it contains the data elements that request clinical information. https://www.hl7.org/fhir/resourcelist.html (accessed at 28.11.2019)

Ajuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial